Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 30, Issue 18, 2012, Pages 2183-2189

  Younes, Anas ^a   Gopal, Ajay K ^b   Smith, Scott E ^d   Ansell, Stephen M ^e   Rosenblatt, Joseph D ^f   Savage, Kerry J ⁿ   Ramchandren, Radhakrishnan ^g   Bartlett, Nancy L ^h   Cheson, Bruce D ⁱ   De Vos, Sven ^j   Forero Torres, Andres ^l   Moskowitz, Craig H ^m   Connors, Joseph M ⁿ   Engert, Andreas ^o   Larsen, Emily K ^c   Kennedy, Dana A ^c   Sievers, Eric L ^c   Chen, Robert ^k  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE GENETICS INC   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j UCLA MEDICAL CENTER   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^o UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SENSORY NEUROPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; RECURRENCE; YOUNG ADULT;

EID: 84863676500     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.0410     Document Type: Article

References (20)

1. Connors JM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 23:6400-6408, 2005
2. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 [Erratum: N Engl J Med 353:744, 2005] (Pubitemid 36682817)
3. Sureda A, Constans M, Iriondo A, et al: Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16:625-633, 2005 (Pubitemid 40613330)
4. Majhail NS, Weisdorf DJ, Defor TE, et al: Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 12:1065-1072, 2006
5. Horning S, Fanale M, deVos S, et al: Defining a population of Hodgkin lymphoma patients for novel therapeutics: An international effort. Ann Oncol 19:118, 2008 (abstr)
6. Dürkop H, Latza U, Hummel M, et al: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421-427, 1992
7. Falini B, Pileri S, Pizzolo G, et al: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1-14, 1995
8. Matsumoto K, Terakawa M, Miura K, et al: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 172:2186-2193, 2004 (Pubitemid 38182365)
9. Sutherland MS, Sanderson RJ, Gordon KA, et al: Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281:10540-10547, 2006 (Pubitemid 43864594)
10. Francisco JA, Cerveny CG, Meyer DL, et al: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465, 2003 (Pubitemid 36988057)
11. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010
12. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
13. Lin DY, Wei LJ: The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84:1074-1078, 1989
14. Bartlett NL, Niedzwiecki D, Johnson JL, et al: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 18:1071-1079, 2007 (Pubitemid 47053777)
15. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 24:1633-1642, 2006 (Pubitemid 46638788)
16. Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin Adv Hematol Oncol 6:455-467, 2008
17. Anderlini P, Saliba R, Acholonu S, et al: Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: The updated M.D. Anderson Cancer Center experience. Haematologica 93:257-264, 2008 (Pubitemid 351397714)
18. Sarina B, Castagna L, Farina L, et al: Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability. Blood 115:3671-3677, 2010
19. Claviez A, Canals C, Dierickx D et al: Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: An analysis of the European Group for Blood and Marrow Transplantation. Blood 114:2060-2067, 2009
20. Chen R, Palmer JM, Popplewell L, et al: Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 90:803-808, 2011